Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 643
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07254390 Effects of Trans-Auricular Vagal Stimulation on Neuromotor Recovery in … |
Active trans-auricular vagus nerv… | SEP | Non applicable | RECRUITING | En attente / non publié | Istituti Clinici Scientifici Maug… | Italy · ICS Maugeri - Montescano, Montescano, Italy | 2025-01-08 → 2027-04-03 | Ouvrir |
| NCT06698328 fMRI Tracking taVNS in ASD |
Transauricular Vagus Nerve Stimul… | SEP | Non applicable | COMPLETED | En attente / non publié | Medical University of South Carol… | United States · 30 Bee Street, Charleston, United Sta… | 2025-02-10 → 2026-02-02 | Ouvrir |
| NCT06996314 Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced B… |
TVNS + Slow-Paced Breathing (TVNS… | SEP | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Ali Kapan | Non communiqué | 2025-09-01 → 2028-08-31 | Ouvrir |
| NCT07633444 TVNS-PAIN — Transauricular Vagus Nerve Stimulation Frequencies for Post… |
Transauricular Vagus Nerve Stimul… | SEP | Non applicable | RECRUITING | En attente / non publié | Federal University of Bahia | Brazil · Hospital Universitário Professor Edgard Sant… | 2026-06-01 → 2026-12-04 | Ouvrir |
| NCT03222973 AFFINITY — Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on The… |
BIIB033 (opicinumab) | SEP | Phase 2 | TERMINATED | En attente / non publié | Biogen | United States, Australia, Belgium, Canada, Czechia, F… | 2017-11-15 → 2021-02-12 | Ouvrir |
| NCT06887426 CLADREXIT — Cladribine Tablets as an Exit Therapy Strategy |
Cladribine | SEP | À vérifier | COMPLETED | En attente / non publié | University Hospital, Strasbourg, … | France · Service de neurologie - Hôpitaux Universitai… | 2025-10-17 → 2026-06-01 | Ouvrir |
| NCT04390009 EPSMS — Entire-body PET Scans for Multiple Sclerosis |
Amyvid radiopharmaceutical | SEP | Phase 1 | RECRUITING | En attente / non publié | Brain Health Alliance | United States · Brain Health Alliance, Ladera Ranch, … | 2024-09-30 → 2028-06-30 | Ouvrir |
| NCT04699747 Investigating the Utility of Demyelination Tracer [18F]3F4AP in Control… |
F-18 3F4AP | SEP | Phase 1 | RECRUITING | En attente / non publié | Massachusetts General Hospital | United States · Massachusetts General Hospital, Bosto… | 2021-03-25 → 2028-09-30 | Ouvrir |
| NCT07282574 Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodyn… |
RO7268489 | SEP | Phase 2 | RECRUITING | En attente / non publié | Hoffmann-La Roche | Australia, Brazil, France, Germany, Hungary, Italy, N… | 2026-03-10 → 2030-05-30 | Ouvrir |
| NCT03109288 Targeting Residual Activity By Precision, Biomarker-Guided Combination … |
Cilostazol | SEP | Phase 1/2 | RECRUITING | En attente / non publié | National Institute of Allergy and… | United States · National Institutes of Health Clinica… | 2017-08-11 → 2029-01-01 | Ouvrir |
| NCT07299019 A Study of Orelabrutinib in Patients With Secondary Progressive Multipl… |
Orelabrutinib | SEP | Phase 3 | RECRUITING | En attente / non publié | Zenas BioPharma (USA), LLC | United States, Bulgaria, Croatia, Czechia, Estonia, G… | 2026-03-23 → 2030-07 | Ouvrir |
| NCT04156243 CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Mali… |
CD19 CARvac T cells | SEP | Phase 1 | UNKNOWN | En attente / non publié | iCell Gene Therapeutics | China · Peking University Shenzhen Hospital, Shenzhen… | 2018-02-01 → 2020-02-28 | Ouvrir |
| NCT03720457 Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed … |
Human CD19 targeted T Cells Injec… | SEP | Phase 1 | UNKNOWN | En attente / non publié | Hrain Biotechnology Co., Ltd. | China · Fudan University Zhongshan Hospital, Shanghai… | 2018-11-13 → 2023-10 | Ouvrir |
| NCT06279923 CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases |
CD19-BAFF Targeted CAR T-cells | SEP | Phase 1 | RECRUITING | En attente / non publié | Zhejiang University | China · The first affiliated hospital of medical coll… | 2024-04-15 → 2027-02-01 | Ouvrir |
| NCT06828042 Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refrac… |
anti-CD19 CAR T cell therapy | SEP | Phase 1/2 | RECRUITING | En attente / non publié | Peking University Third Hospital | China · Peking University Third Hospital, Beijing, Ch… | 2025-07-01 → 2027-12-31 | Ouvrir |
| NCT07582159 Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chro… |
Acalabrutinib | SEP | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | City of Hope Medical Center | United States · City of Hope at Irvine Lennar, Irvine… | 2026-12-19 → 2029-04-14 | Ouvrir |
| NCT03824951 Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymp… |
Anti-CD19 iCAR NK Cells | SEP | Phase 1 | UNKNOWN | En attente / non publié | Allife Medical Science and Techno… | Non communiqué | 2019-02-01 → 2021-01-01 | Ouvrir |
| NCT04486872 An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of D… |
Autologous humanized anti-CD19 an… | SEP | Phase 1 | UNKNOWN | En attente / non publié | First Affiliated Hospital of Zhej… | China · First Affiliated Hospital of Zhejiang Univers… | 2020-07-25 → 2022-06-25 | Ouvrir |
| NCT06591429 Smoldering Inflammation in MS |
Radiotracer [11C]-CS1P1 | SEP | À vérifier | RECRUITING | En attente / non publié | Washington University School of M… | United States · Barnes Jewish Center for Clinical Ima… | 2024-06-19 → 2027-06-30 | Ouvrir |
| NCT02538926 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxor… |
Asparaginase | SEP | Phase 2 | WITHDRAWN | En attente / non publié | University of Washington | United States · Fred Hutchinson Cancer Research Cente… | 2018-07-01 → 2021-07-30 | Ouvrir |
| NCT00003595 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in… |
Filgrastim | SEP | Phase 3 | COMPLETED | En attente / non publié | National Cancer Institute (NCI) | United States · Arthur G. James Cancer Hospital - Ohi… | 1999-01 | Ouvrir |
| NCT07110194 Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positi… |
TQB2825 Injection (Subcutaneous I… | SEP | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Shanghai Chia Tai Tianqing Pharma… | China · Beijing Cancer Hospital, Beijing, China | 2025-09 → 2027-12 | Ouvrir |
| NCT04361279 A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previo… |
SIBP-02 | SEP | Phase 3 | COMPLETED | En attente / non publié | Shanghai Institute Of Biological … | China · The First Affiliated Hospital of College of M… | 2019-07-25 → 2022-05-20 | Ouvrir |
| NCT00818961 Donor Stem Cell Transplant in Treating Patients With High-Risk Hematolo… |
Alemtuzumab | SEP | Phase 2 | TERMINATED | En attente / non publié | Northwestern University | United States · Blood and Marrow Transplant Group of … | 2005-05 → 2012-03 | Ouvrir |
| NCT03379051 Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ubli… |
Venetoclax | SEP | Phase 1/2 | TERMINATED | En attente / non publié | National Cancer Institute (NCI) | United States · TG Therapeutics Investigational Trial… | 2018-03-27 → 2022-06-16 | Ouvrir |